Company / Cash & Equivalents
Surgery Partners, Inc. Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$269.5M
FY2024
5-year range
$195.9M / $389.9M
FY2020-FY2024
Trend
+37.6%
vs FY2023
Sector context
#70 of 148
Health Care
What the data says
At $270M, Surgery Partners, Inc.'s cash & equivalents ranks #70 of 148 in the Health Care sector. Cash & Equivalents returned to growth in FY2024 after 2 years of decline, reaching $270M.
Based on SEC 10-K filings.
$270M in FY2024 with a 5-year CAGR of +23.8%.
Declined from $283M to $270M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -11.6%
- 5-Year CAGR
- +23.8%
- 10-Year CAGR
- -
Sector benchmark
#70 of 148 in Health CareTop 47% of 148This company $269.5M Sector average $1.2B
▼
-77.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +23.8%, indicating consistent growth.
- In FY2024, cash & equivalents increased 37.6% year-over-year.
- Ranks #70 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.31 (distress zone, below 1.8 threshold)
- Negative profit margin: -14.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $269.5M | +37.6% |
| FY2023 | $195.9M | -30.8% |
| FY2022 | $282.9M | -27.4% |
| FY2021 | $389.9M | +22.6% |
| FY2020 | $317.9M | +242.9% |
| FY2019 | $92.7M | -49.7% |
| FY2018 | $184.3M | +5.4% |
| FY2017 | $174.9M | +151.0% |
| FY2016 | $69.7M | +20.3% |
| FY2015 | $57.9M | -22.7% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026